Rotigaptide
Highest phase reached
Phase 2
Drug type
Protein
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Protein
- Drug name
- Rotigaptide
- Molecular weight
- 617.66
- Structure (SMILES)
- CC(=O)N[C@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@@H]1C(=O)N1C[C@@H](O)C[C@@H]1C(=O)NCC(=O)N[C@H](C)C(=O)NCC(N)=O
- GAP (WYETH)
- gap 486 zp 123
- gap wyeth
- GAP-486 (ZP-123)
- Prevnar®: (Wyeth)
- rotigaptida
- Rotigaptida
- rotigaptide
- Rotigaptide
- rotigaptide [INN]
- ROTIGAPTIDE [USAN]
- rotigaptide inn
- rotigaptide usan
- The conjugate vaccine used is Prevnar (Wyeth-Ayerst vaccines)
- zp 123
- zp 123 zealand
- ZP-123
- ZP-123 (ZEALAND)
- CAS registry numbers
- 355151-12-1
- ChEMBL ID
- CHEMBL450656
- InChIKey
- GFJRASPBQLDRRY-TWTQBQJDSA-N
- PubChem compound IDs
- 9938933
- FDA ingredient codes (UNII)
- GFA1W6KO7N
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- rotigaptide
- Type
- Peptide
- Drug name stem
- -tide
Investigated indications
- Condition
- Arrhythmias, Cardiac
- Highest recorded phase
- 2
- Condition identifier
- EFO:0004269
- Subject identifier
- D001145
- Condition identifier
- EFO_0004269
- Highest recorded phase
- 2
- Condition identifier
- EFO_1001461
- Condition identifier
- HP_0004308
- Highest recorded phase
- 2
- Condition identifier
- HP_0011675
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005068
- NCT00137293
- NCT00137332
- Hydrogen bond acceptors
- 9
- Hydrogen bond donors
- 7
- Polar surface area
- 240.57
- Calculated partition coefficient (ALogP)
- -3.39
- Calculated partition coefficient (XLogP)
- -2.3
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 2
- Rotatable bonds
- 12
- Heavy atoms
- 44
- Molecular formula
- C28H39N7O9
- Monoisotopic mass
- 617.28092585
- Natural product
- Yes
- Recorded assays
- 7
- Active assays
- 0
Related records
Trials (102)
- A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- A Phase 1b Clinical Trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine
- A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infants
- A Phase 2, Multicenter, Open-label Study to Assess the Immunogenicity of an Investigational Hib Vaccine (NU300)in Toddlers
- A Phase III Clinical Trial of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants
- A Protocol to Collect Human Serum Samples From Healthy Adults for Use as Quality Controls Samples in GlaxoSmithKline (GSK) Biologicals' Assays
- A Study of Pneumococcal Conjugate Vaccine (V114) Compared to a Marketed Vaccine (V114-003)
- A Study of Three Different Doses of VAC52416 (ExPEC10V) in Adults Aged 60 to 85 Years in Stable Health
- A Study of V118 Formulation C (V118C) in Healthy Participants (V118C-001)
- A Study of V118E in Healthy Participants (V118E-003)
- A Study of V132 in Healthy Older Participants (V132-001)
- A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006)
- A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks)
- A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION)
- A Study to Evaluate the Safety and Tolerability of V114 and Prevnar 13™ in Healthy Infants (V114-031/PNEU-LINK)
- A Study to Evaluate the Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-005)
- A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Lots of V114 in Healthy Infants (V114-008)
- A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)
- A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)
- A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)
In development for (1)
- Cardiac rhythm disease Phase 2